Nevirapine still a treatment option for mother to child transmission
Anti-AIDS drug Nevirapine remains an option for the treatment of mother to child transmission despite the deaths of five women during the course of a local trial involving the drug, according to Health minister Dr Manto Tshabalala-Msimang.
She said yesterday (Thursday) that she had “just a while ago signed letter to support the studies being done at Bara (Chris Hani Baragewanath Hospital)”.
“We have even asked them to ensure that they have more than one site so we can get really good results,” Tshabalala-Msimang said.
The Baragwanath site, where the SAINT trials were being conducted, compared Nevirapine with short course AZT and 3TC for safety and efficacy for mother to child transmission.
Nevirapine has not yet been registered in South Africa for paediatric use.
The minister reiterated that government had not stopped any other trials other than the FTC 302 trial in Port Elizabeth being conducted by Quintiles Clindepharm, that involved the five deaths.
“I was talking about one study, the FTC study,” Tshabalala-Msimang said, referring to some news reports that she had halted all Nevirapine trials.
“As a result of the deaths the Medicines Control Council (MCC) has halted any further recruitment of study subjects (in the FTC 302 trial), while full reports are being compiled on all serious adverse events, including the five deaths,” she said.
Tshabalala-Msimang said the US Food and Drug Administration had agreed with the MCC decision to halt the FTC 302 trial.
Clindepharm was conducting the trial on behalf of Triangle Pharmaceuticals, a US company.
She confirmed that two of the deaths were due to hepatitis. According to a reliable source it appeared at this stage as if a third death was also not related to the drug trial.
According to an MCC report handed to the minister 510 patients had been recruited. The trial aimed to compare FTC with Lamivudine in a triple combination regimen in people who were HIV positive and who had not yet taken any antiretroviral drugs.
The trial had two groups. One group received FTC and the other Lamivudine.
Within each group, there were three sub-groups of patients.
The patients in sub-group one and two received Nevirapine as part of their drug cocktail and sub-group three did not.
Tshabalala-Msimang said she had also asked for a comprehensive report on all HIV/AIDS related clinical trials approved by the MCC that are currently running in South Africa, or that have been completed in the past five years.
* Tshabalala-Msimang said the treatment guidelines for HIV/AIDS patients were in the process of being printed.
She said the delay had been caused around issues on the management of psychiatric patients.
“We agreed on everything in February already, we just had to clarify some issues around referral guidelines for psychiatric patients,” Tshabalala-Msimang said.
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Nevirapine still a treatment option for mother to child transmission
by Anso Thom, Health-e News
April 7, 2000